| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
20B Stock Overview
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment.
BioMark Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.19 |
| 52 Week High | €0.23 |
| 52 Week Low | €0.11 |
| Beta | 0.68 |
| 1 Month Change | -0.53% |
| 3 Month Change | 40.91% |
| 1 Year Change | 28.28% |
| 3 Year Change | 186.60% |
| 5 Year Change | 220.69% |
| Change since IPO | -71.65% |
Recent News & Updates
Shareholder Returns
| 20B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.6% | 1.2% | 1.0% |
| 1Y | 28.3% | -0.5% | -20.4% |
Return vs Industry: 20B exceeded the German Biotechs industry which returned -2.5% over the past year.
Return vs Market: 20B exceeded the German Market which returned -20.5% over the past year.
Price Volatility
| 20B volatility | |
|---|---|
| 20B Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 20B is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: 20B's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Rashid Ahmed Bux | https://www.biomarkdiagnostics.com |
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
BioMark Diagnostics Inc. Fundamentals Summary
| 20B fundamental statistics | |
|---|---|
| Market Cap | CA$20.52m |
| Earnings (TTM) | -CA$1.45m |
| Revenue (TTM) | CA$43.93k |
469.3x
P/S Ratio-14.1x
P/E RatioIs 20B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 20B income statement (TTM) | |
|---|---|
| Revenue | CA$43.93k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$43.93k |
| Other Expenses | CA$1.50m |
| Earnings | -CA$1.45m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,309.36% |
| Debt/Equity Ratio | -37.8% |
How did 20B perform over the long term?
See historical performance and comparison